


Name of Policy: Documentation/Record-keeping/Record Review		 Effective date: 01/04/2025 Original effective date: 10/06/2003	
Policy Number: 3364-107-311			
Approving Officer: Medical Director, Clinical Pathology			
Responsible Agent: Director, Clinical Pathology Administrative Director, Lab			
Scope: Pathology Laboratory University of Toledo Medical Center			
Key words: Uniform format, documentation, requisitions, results reporting, transfusion reactions.			
<input type="checkbox"/>	New policy proposal	<input type="checkbox"/>	Minor/technical revision of existing policy
<input type="checkbox"/>	Major revision of existing policy	<input checked="" type="checkbox"/>	Reaffirmation of existing policy

(A) Policy statement

The Laboratory provides a uniform format for documentation relating to requisition, performance and reporting test results in the form of records, procedures, and policies and retains these records for the time specified by CLIA, FDA, CAP and standards.

(B) Purpose of policy

To describe a system of generation, implementation, revision, and review of all records pertinent to the care of patients at UTMC.

(C) Procedure

1. The following records must be maintained for at least two years: Specimen requisitions, patient test results and reports (electronic computer retrieval is acceptable), accession records, quality control records, proficiency test records, quality improvement records.
2. Format and revisions of forms or records that will be part of the patient’s permanent medical record must be reviewed and approved by the UTMC Forms Committee. These forms must be submitted for review to the Medical Records department and bear a Medical Record form number.
3. A designated Technologist or Supervisor reviews the following:
 - Follow-Up Work Lists:
 - a. Criticals,
 - b. Delta Checks,
 - c. Abnormals,

d. Comm Log.

- Monthly results of reagent quality control, instrument function checks and equipment temperature monitoring.
- POCT results and QC.

4. The Medical Director reviews the following:

- Special Studies, including antibody identifications and elution studies, electrophoresis reports, coagulation studies, immunofluorescence studies. Written reports, if necessary, are signed before release.
- Transfusion reaction investigations. Results are interpreted, reported and signed by the Medical Director.

<p>Approved by:</p> <p>/s/</p> <hr/> <p>Name: Amira Gohara, M.D. Title: Medical Director, Clinical Pathology</p> <p>1/10/2025</p> <hr/> <p>Date</p> <p><i>Review/Revision Completed by:</i></p> <p><i>Joshua Otiso, Administrative Director, Lab</i></p>	<p>Policies Superseded by This Policy:</p> <ul style="list-style-type: none">• <i>Q-10</i> <p>Initial effective date: 10/06/2003</p> <p>Review/Revision Date: 01/04/2025</p> <p>Next review date: 01/04/2027</p>
--	---